Ursolic acid prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPARα

Zhang,Yanan; Song,Chengwei; Li,Haiou; Hou,Jingdong; Li,Dongliang

doi:10.3892/mmr.2016.5172

Ursolic acid prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPARα

Authors:
- Yanan Zhang
- Chengwei Song
- Haiou Li
- Jingdong Hou
- Dongliang Li
View Affiliations

Affiliations: Department of Anesthesiology, Jining First People's Hospital, Jining, Shandong 272011, P.R. China, Department of Anesthesiology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: April 22, 2016 https://doi.org/10.3892/mmr.2016.5172
Pages: 5309-5316

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Obesity is a risk factor for several pain syndromes and is associated with increased pain sensitivity. Evidence suggests that obesity causes the downregulation of peroxisome proliferator‑activated receptor (PPAR)α in the spinal cord, contributing to augmented peripheral edema and inflammatory hyperalgesia. Ursolic acid (UA), a natural pentacyclic triterpenoid carboxylic acid, has been shown to upregulate PPARα in the peripheral tissues of obese animals. The present study hypothesized that UA prevents augmented peripheral inflammation and inflammatory hyperalgesia in obesity by restoring downregulated spinal PPARα. The present study demonstrated that Sprague‑Dawley rats fed a high‑fat diet (HFD) for 12 weeks developed obesity and metabolic disorder. Following carrageenan injection, the HFD rats exhibited increased thermal hyperalgesia and paw edema, compared with the rats fed a low‑fat diet. Molecular investigations revealed that the HFD rats exhibited decreased PPARα activity, and exaggerated expression of inflammatory mediators and nuclear factor‑kB activity in the spinal cord in response to carrageenan. Oral administration of UA ameliorated obesity and metabolic disorder, and prevented increased thermal hyperalgesia and paw edema in the HFD rats. Additionally, UA normalized PPARα activity and inhibited the exaggerated spinal cord inflammatory response to carrageenan. Although the knockdown of spinal PPARα with small interfering RNA following the administration of UA did not alter obesity or metabolic parameters, it eradicated the beneficial effects of UA on thermal hyperalgesia and paw edema, and reversed the spinal cord inflammatory response. These results suggested that the systemic administration of UA inhibited the exaggerated spinal cord inflammatory response to peripheral inflammatory stimulation in HFD‑induced obesity by restoring downregulated spinal PPARα, preventing peripheral inflammation and inflammatory hyperalgesia. UA may be a potential therapeutic option for the prevention of increased inflammatory pain in obese patients.

View Figures

View References

1	Prentice AM: The emerging epidemic of obesity in developing countries. Int J Epidemiol. 35:93–99. 2006. View Article : Google Scholar
2	Hurt RT, Kulisek C, Buchanan LA and McClave SA: The obesity epidemic: Challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol (NY). 6:780–792. 2010.
3	Jankun J, Al-Senaidy A and Skrzypczak-Jankun E: Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review) Int J Mol Med. 29:3–11. 2012.
4	Marcus DA: Obesity and the impact of chronic pain. Clin J Pain. 20:186–191. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hitt HC, McMillen RC, Thornton-Neaves T, Koch K and Cosby AG: Comorbidity of obesity and pain in a general population: Results from the southern pain prevalence study. J Pain. 8:430–436. 2007. View Article : Google Scholar : PubMed/NCBI
6	D'Arcy Y: Managing pain in obese patients. Nurse Pract. 36:28–32; quiz 33. 2011. View Article : Google Scholar : PubMed/NCBI
7	Patterson RE, Frank LL, Kristal AR and White E: A comprehensive examination of health conditions associated with obesity in older adults. Am J Prev Med. 27:385–390. 2004. View Article : Google Scholar : PubMed/NCBI
8	Roane DS and Porter JR: Nociception and opioid-induced analgesia in lean (Fa/-) and obese (fa/fa) Zucker rats. Physiol Behav. 38:215–218. 1986. View Article : Google Scholar : PubMed/NCBI
9	Croci T and Zarini E: Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br J Pharmacol. 150:559–566. 2007. View Article : Google Scholar : PubMed/NCBI
10	Iannitti T, Graham A and Dolan S: Increased central and peripheral inflammation and inflammatory hyperalgesia in Zucker rat model of leptin receptor deficiency and genetic obesity. Exp Physiol. 97:1236–1245. 2012. View Article : Google Scholar : PubMed/NCBI
11	D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Raso GM, Cuzzocrea S, Lo Verme J, Piomelli D, et al: Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther. 322:1137–1143. 2007. View Article : Google Scholar : PubMed/NCBI
12	Wang J, Zhang Q, Zhao L, Li D, Fu Z and Liang L: Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats. Neuroscience. 278:165–178. 2014. View Article : Google Scholar : PubMed/NCBI
13	Jia Y, Bhuiyan MJ, Jun HJ, Lee JH, Hoang MH, Lee HJ, Kim N, Lee D, Hwang KY, Hwang BY, et al: Ursolic acid is a PPAR-α agonist that regulates hepatic lipid metabolism. Bioorg Med Chem Lett. 21:5876–5880. 2011. View Article : Google Scholar : PubMed/NCBI
14	Li S, Liao X, Meng F, Wang Y, Sun Z, Guo F, Li X, Meng M, Li Y and Sun C: Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One. 9:e867242014. View Article : Google Scholar : PubMed/NCBI
15	Liu J: Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol. 49:57–68. 1995. View Article : Google Scholar : PubMed/NCBI
16	Ikeda Y, Murakami A and Ohigashi H: Ursolic acid: An anti- and pro-inflammatory triterpenoid. Mol Nutr Food Res. 52:26–42. 2008. View Article : Google Scholar : PubMed/NCBI
17	Kim M, Sung B, Kang YJ, Kim DH, Lee Y, Hwang SY, Yoon JH, Yoo MA, Kim CM, Chung HY and Kim ND: The combination of ursolic acid and leucine potentiates the differentiation of C2C12 murine myoblasts through the mTOR signaling pathway. Int J Mol Med. 35:755–762. 2015.
18	Vasconcelos MA, Royo VA, Ferreira DS, Crotti AE, Andrade e Silva ML, Carvalho JC, Bastos JK and Cunha WR: In vivo analgesic and anti-inflammatory activities of ursolic acid and oleanoic acid from Miconia albicans (Melastomataceae). Z Naturforsch C. 61:477–482. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zhou Y, Li JS, Zhang X, Wu YJ, Huang K and Zheng L: Ursolic acid inhibits early lesions of diabetic nephropathy. Int J Mol Med. 26:565–570. 2010.PubMed/NCBI
20	Tsai SJ and Yin MC: Antioxidative and anti-inflammatory protection of oleanolic acid and ursolic acid in PC12 cells. J Food Sci. 73:H174–H178. 2008. View Article : Google Scholar : PubMed/NCBI
21	Martin R, Carvalho-Tavares J, Hernández M, Arnés M, Ruiz-Gutierrez V and Nieto ML: Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: A potential therapeutic role. Biochem Pharmacol. 79:198–208. 2010. View Article : Google Scholar
22	Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang-Christensen M, Hansen HS, Levin BE, Larsen PJ, Knudsen LB, Fosgerau K and Vrang N: Long-term characterization of the diet-induced obese and diet-resistant rat model: A polygenetic rat model mimicking the human obesity syndrome. J Endocrinol. 206:287–296. 2010. View Article : Google Scholar : PubMed/NCBI
23	D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, et al: Central administration of palmitoylethanolamide reduces hyper-algesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol. 613:54–59. 2009. View Article : Google Scholar : PubMed/NCBI
24	Ichitani Y, Shi T, Haeggstrom JZ, Samuelsson B and Hökfelt T: Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inflammation: An in situ hybridization study. Neuroreport. 8:2949–2952. 1997. View Article : Google Scholar : PubMed/NCBI
25	Samad T and Abdi S: Cyclooxygenase-2 and antagonists in pain management. Curr Opin Anaesthesiol. 14:527–532. 2001. View Article : Google Scholar
26	Kota BP, Huang TH and Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res. 51:85–94. 2005. View Article : Google Scholar : PubMed/NCBI
27	Moreno S, Farioli-Vecchioli S and Cerù MP: Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 123:131–145. 2004. View Article : Google Scholar
28	Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 53:409–435. 2002. View Article : Google Scholar : PubMed/NCBI
29	Filip-Ciubotaru F, Foia L, Manciuc C and Grigore C: PPARs: Structure, mechanisms of action and control. Note I. Rev Med Chir Soc Med Nat Iasi. 115:477–484. 2011.In Romanian. PubMed/NCBI
30	Duval C, Fruchart JC and Staels B: PPAR alpha, fibrates, lipid metabolism and inflammation. Arch Mal Coeur Vaiss. 97:665–672. 2004.PubMed/NCBI
31	Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Muià C, Crisafulli C and Caputi AP: The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol. 79:999–1010. 2006. View Article : Google Scholar : PubMed/NCBI
32	Auphan N, DiDonato JA, Rosette C, Helmberg A and Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 270:286–290. 1995. View Article : Google Scholar : PubMed/NCBI
33	George A, Marziniak M, Schäfers M, Toyka KV and Sommer C: Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 88:267–275. 2000. View Article : Google Scholar : PubMed/NCBI
34	Zhao W, Iskandar S, Kooshki M, Sharpe JG, Payne V and Robbins ME: Knocking out peroxisome proliferator-activated receptor (PPAR) alpha inhibits radiation-induced apoptosis in the mouse kidney through activation of NF-kappaB and increased expression of IAPs. Radiat Res. 167:581–591. 2007. View Article : Google Scholar : PubMed/NCBI
35	Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B and Haegeman G: A paradigm for gene regulation: Inflammation, NF-kappaB and PPAR. Adv Exp Med Biol. 544:181–196. 2003. View Article : Google Scholar
36	Lu J, Wu DM, Zheng YL, Hu B, Zhang ZF, Ye Q, Liu CM, Shan Q and Wang YJ: Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-κB pathway activation. Cereb Cortex. 20:2540–2548. 2010. View Article : Google Scholar : PubMed/NCBI